CA2419047A1 - Water-soluble prodrugs of propofol for treatment of migraine - Google Patents

Water-soluble prodrugs of propofol for treatment of migraine Download PDF

Info

Publication number
CA2419047A1
CA2419047A1 CA002419047A CA2419047A CA2419047A1 CA 2419047 A1 CA2419047 A1 CA 2419047A1 CA 002419047 A CA002419047 A CA 002419047A CA 2419047 A CA2419047 A CA 2419047A CA 2419047 A1 CA2419047 A1 CA 2419047A1
Authority
CA
Canada
Prior art keywords
propofol
migraine
water
pharmaceutically acceptable
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002419047A
Other languages
English (en)
French (fr)
Inventor
Sheldon S. Hendler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
374Water Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2419047A1 publication Critical patent/CA2419047A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002419047A 2000-08-15 2001-08-14 Water-soluble prodrugs of propofol for treatment of migraine Abandoned CA2419047A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/639,015 US6362234B1 (en) 2000-08-15 2000-08-15 Water-soluble prodrugs of propofol for treatment of migrane
US09/639,015 2000-08-15
PCT/US2001/025540 WO2002013810A1 (en) 2000-08-15 2001-08-14 Water-soluble prodrugs of propofol for treatment of migraine

Publications (1)

Publication Number Publication Date
CA2419047A1 true CA2419047A1 (en) 2002-02-21

Family

ID=24562380

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002419047A Abandoned CA2419047A1 (en) 2000-08-15 2001-08-14 Water-soluble prodrugs of propofol for treatment of migraine

Country Status (5)

Country Link
US (1) US6362234B1 (https=)
EP (1) EP1318798A4 (https=)
JP (1) JP2004517810A (https=)
CA (1) CA2419047A1 (https=)
WO (1) WO2002013810A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
DE69912441T2 (de) 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
NZ533536A (en) * 2001-12-28 2006-11-30 Mgi Gp Inc Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol such as O-phosphonooxymethyl propofol
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
HUP0600241A2 (en) * 2002-04-08 2006-07-28 Mgi Gp Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
DE20215415U1 (de) * 2002-10-08 2004-02-26 Biotechnologie Gesellschaft Mittelhessen Mbh Wasserlösliche Medikamentenvorstufen von Propofol
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
ZA200504940B (en) * 2003-01-28 2006-09-27 Xenoport Inc Amino acid derived prodrugs of propofol, compositions and uses thereof
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US7230003B2 (en) * 2003-09-09 2007-06-12 Xenoport, Inc. Aromatic prodrugs of propofol, compositions and uses thereof
US7250412B2 (en) * 2003-10-24 2007-07-31 Auspex Pharmaceuticals, Inc. PH sensitive prodrugs of 2,6-Diisopropylphenol
BRPI0417472A (pt) * 2003-12-17 2007-05-08 Mgi Gp Inc métodos para administração de prodrogas de propofol solúveis em água para sedação prolongada
DE602005010270D1 (de) * 2004-07-12 2008-11-20 Xenoport Inc Von aminosäuren abgeleitete prodrugs von propofolzusammensetzungen und anwendungen davon
US7241807B2 (en) 2004-07-12 2007-07-10 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
WO2006033911A2 (en) * 2004-09-17 2006-03-30 Mgi Gp, Inc. Methods of administering water-soluble prodrugs of propofol
EP1844000B1 (en) * 2004-12-23 2010-01-27 Xenoport, Inc. Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
WO2007022437A2 (en) * 2005-08-18 2007-02-22 Auspex Pharmaceuticals, Inc. Therapeutic agents for the treatment of cancer and metabolic disorders
US7589239B2 (en) * 2005-09-02 2009-09-15 Auspex Pharmaceuticals Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
MY147215A (en) 2007-05-09 2012-11-14 Pharmacofore Inc Therapeutic compunds
CN101715437B (zh) 2007-05-09 2013-06-12 特色疗法股份有限公司 立体异构异丙酚治疗性化合物
WO2008157627A1 (en) * 2007-06-21 2008-12-24 Xenoport, Inc. Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus
US20090076141A1 (en) * 2007-09-14 2009-03-19 Xenoport, Inc. Use of Propofol Prodrugs for Treating Neuropathic Pain
GB0905834D0 (en) 2009-04-03 2009-05-20 Seps Pharma Nv Phosphonyl-containing phenolic derivatives useful as medicaments
CN101575349B (zh) * 2009-06-11 2011-07-20 中国科学院广州化学研究所 一种丙泊酚磷酸酯二钠盐的制备方法
EP2531047B1 (en) 2010-02-05 2024-11-13 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
JP5399944B2 (ja) * 2010-02-25 2014-01-29 信越化学工業株式会社 リン酸エステル基含有オルガノポリシロキサンの製造方法
JP5502540B2 (ja) * 2010-03-19 2014-05-28 信越化学工業株式会社 リン酸エステル基含有オルガノポリシロキサンの製造方法
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
WO2011161687A1 (en) 2010-06-23 2011-12-29 Harman Finochem Limited Process for preparing extra pure 2, 6-diisopropyl phenol
CN101885735B (zh) * 2010-06-23 2012-09-12 四川大学华西医院 取代苯酚羟基酸酯的磷酸酯化合物、制备方法及在药物中的应用
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
CN102260184B (zh) * 2011-06-09 2014-07-02 浙江九旭药业有限公司 丙泊酚衍生物及其制备方法和应用
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
US11331271B2 (en) 2016-05-27 2022-05-17 The Johns Hopkins University Buccal, sublingual and intranasal delivery of fospropofol
IL267006B2 (en) 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
US12358863B2 (en) 2019-10-22 2025-07-15 West China Hospital, Sichuan University Nitrogen-containing derivative of substituted phenol hydroxy acid ester, and preparation and use thereof
EP3912621A1 (en) * 2020-05-19 2021-11-24 tesa Labtec GmbH Propofol for diagnosis of primary headache

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
JPH08339002A (ja) * 1995-04-10 1996-12-24 Ngk Insulators Ltd 第二高調波発生素子およびその製造方法
US5891875A (en) * 1996-05-20 1999-04-06 Eli Lilly And Company Morpholinyl tachykinin receptor antagonists
US6254853B1 (en) * 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols

Also Published As

Publication number Publication date
US6362234B1 (en) 2002-03-26
JP2004517810A (ja) 2004-06-17
EP1318798A4 (en) 2004-01-28
EP1318798A1 (en) 2003-06-18
WO2002013810A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
US6362234B1 (en) Water-soluble prodrugs of propofol for treatment of migrane
US6254853B1 (en) Water soluble pro-drugs of propofol
KR100400075B1 (ko) 세포로의침투가개선된약제
US20130225529A1 (en) Phospho-ester derivatives and uses thereof
US20090275545A1 (en) Medicinal targeted local lipolysis
JPWO1991010431A1 (ja) 脂肪乳剤
EP1515711A1 (en) Pharmaceutical composition
US12102616B2 (en) Psilocin mucate
WO2011135020A1 (de) Verwendung einer phospholipid und glycyrrhizinsäure enthaltenden zusammensetzung zur entfernung von subkutanen fettansammlungen durch subkutane lipolyse
JP3036881B2 (ja) ビロバリデ誘導体、この用途及びこれを含有する薬剤組成物
PT1771155E (pt) Método e composição para o tratamento da rinite
WO1999024400A1 (en) Probucol esters and uses thereof
EP2098237A1 (en) Analgesic agent comprising cyclic phosphatidic acid derivative
JPS637526B2 (https=)
EP0661053A1 (en) Use of tocopherol ascorbic adic phosphates for hemorrhoidal diseases
EP1140115B1 (en) Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents
EP0166436A2 (en) Use of dolichol or its ester in medicines
KR950005914B1 (ko) Nmda-차단 제약조성물
JP2002524016A (ja) イノシトールポリホスフェート誘導体およびその使用方法
US5041450A (en) Treatment of ocular inflammation
KR100187652B1 (ko) 지방성 유화액
KR101198201B1 (ko) 비염 치료를 위한 방법 및 조성물
WO2001055083A1 (en) Inositol derivatives and their pharmaceutical use

Legal Events

Date Code Title Description
FZDE Discontinued